General Cardiology
HCM, DCM, and other cardiomyopathies
Also called HCM, DCM, hypertrophic cardiomyopathy, dilated cardiomyopathy
Sources: updated Oct 1, 2026
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Synthesized from 3 evidence-backed clinical questions on Cardiomyopathy — 1 supports benefit, 2 no benefit shown.
The placed evidence leans toward no benefit
1
Favor benefit
33% of all
2
No benefit shown
67% of all
Low certainty on 100% of questions
Does chimeric antigen receptor t cells vs placebo improve outcomes in Myocardial fibrosis?
Low Certainty− No benefit shownchimeric antigen receptor t cells vs placebo · Myocardial Infarction Hospitalization
9 studies (106,960 patients) provide low-certainty evidence against benefit of chimeric antigen receptor t cells for Myocardial Infarction Hospitalization in Myocardial fibrosis.
Does trastuzumab vs placebo improve outcomes in HER2-positive carcinoma of breast?
Low Certainty− No benefit showntrastuzumab vs placebo · Cardiac Index
12 studies (331 patients) provide low-certainty evidence against benefit of trastuzumab for Cardiac Index in HER2-positive carcinoma of breast.
Does carvedilol vs adriamycin improve Myopathy / Rhabdomyolysis in Nijmegen Breakage Syndrome?
Low Certainty+ Favors benefitcarvedilol vs Adriamycin · Myopathy / Rhabdomyolysis
3 studies (81 patients) provide low-certainty evidence for benefit of carvedilol for Myopathy / Rhabdomyolysis in Nijmegen Breakage Syndrome.
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.